祥生医疗(688358) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue was CNY 105,410,236.43, a decrease of 16.22% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 29,467,368.71, down 40.90% year-on-year[5] - Basic and diluted earnings per share were both CNY 0.26, reflecting a decline of 42.22% year-on-year[6] - Net profit for the third quarter of 2023 was ¥141,432,208.56, compared to ¥125,599,972.62 in the same quarter of 2022, indicating an increase of approximately 12.6%[21] - The total comprehensive income for the third quarter of 2023 was ¥141,602,414.23, compared to ¥125,448,478.06 in the same quarter of 2022, reflecting an increase of about 12.9%[21] Cash Flow - Cash flow from operating activities for the quarter was CNY 11,960,839.91, a decrease of 27.14% compared to the previous year[6] - Net cash flow from operating activities for the first nine months of 2023 was CNY 47,503,874.22, an increase of 65.2% compared to CNY 28,769,350.89 in the same period of 2022[22] - Cash inflow from sales of goods and services for the first nine months of 2023 was CNY 311,541,393.39, a decrease of 6.5% from CNY 333,353,491.17 in the same period of 2022[22] - Cash outflow for purchasing goods and services was CNY 154,954,131.42, down from CNY 179,784,478.78 in the previous year, reflecting a reduction of 13.8%[22] - The company reported a net cash outflow from financing activities of CNY 83,931,675.80 in 2023, compared to a net outflow of CNY 38,445,962.03 in 2022, indicating a worsening of 118.5%[23] Assets and Liabilities - Total assets at the end of the quarter were CNY 1,495,958,152.96, a decrease of 1.19% from the end of the previous year[6] - The company's total liabilities decreased to ¥120,599,793.97 in Q3 2023 from ¥200,418,411.27 in Q3 2022, a reduction of about 39.8%[20] - The total equity attributable to shareholders increased to ¥1,375,358,358.99 in Q3 2023, up from ¥1,313,508,192.90 in Q3 2022, representing a growth of approximately 4.7%[20] - Current liabilities decreased to ¥111,088,353.15 from ¥188,470,568.81 year-over-year[16] - The company's fixed assets are valued at ¥74,301,804.23, a decrease from ¥79,168,596.53[16] Research and Development - R&D expenses totaled CNY 21,274,268.90, a decrease of 9.92% compared to the same quarter last year[6] - R&D investment as a percentage of revenue increased to 20.18%, up 1.41 percentage points from the previous year[6] - Research and development expenses for the third quarter of 2023 were ¥58,937,647.88, slightly down from ¥62,010,190.82 in the same quarter of 2022, a decrease of about 5.5%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,556[11] - The top shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 45,360,000 shares, accounting for 40.46% of the total shares[11] - The top ten shareholders collectively hold a significant portion of the company's shares, indicating concentrated ownership[12] - The company has no preferred shareholders as of the reporting date[11] Market and Operational Challenges - The company experienced foreign exchange losses due to fluctuations in the USD exchange rate impacting net profit[10] - The decline in net profit was also attributed to delays in fulfilling certain orders due to material shortages[10] - The company has not disclosed any significant new product developments or market expansion strategies in this report[13] Other Financial Metrics - The weighted average return on equity was 2.16%, a decrease of 1.65 percentage points year-on-year[6] - The company's cash and cash equivalents as of September 30, 2023, amount to ¥624,311,194.22, an increase from ¥446,198,990.53 at the end of 2022[15] - Accounts receivable increased to ¥180,640,765.90 from ¥93,521,760.48 year-over-year[15] - Deferred income tax liabilities rose to ¥242,873.61 in Q3 2023 from ¥152,538.68 in Q3 2022, an increase of approximately 59.3%[20] - The impact of exchange rate changes on cash and cash equivalents was CNY 11,602,462.84, down from CNY 27,799,977.12 in the previous year, a decrease of 58.3%[23]